

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	663	(544/198).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/08/07 14:16
L2	424	(544/207).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/08/07 14:16
L3	781	(514/241).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/08/07 14:16

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	663	(544/198).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/08/07 14:16
L2	424	(544/207).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/08/07 14:16
L3	781	(514/241).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/08/07 14:16

10/673,521

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/Caplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/Caplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN

10/673,521

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:00:56 ON 07 AUG 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:01:01 ON 07 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 AUG 2005 HIGHEST RN 858648-31-4  
DICTIONARY FILE UPDATES: 5 AUG 2005 HIGHEST RN 858648-31-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005 .

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Documents and Settings\VBalasubramania\My Documents\STNEXP4\QUERIES\10673521.str

10/673,521



chain nodes :

7 8 9 10 11 12 13 14 15 16 20

ring nodes :

1 2 3 4 5 6

chain bonds :

2-13 4-20 6-12 7-8 9-10 9-11 12-14 13-16 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-13 4-20 6-12 9-10 12-14 13-16 14-15

exact bonds :

7-8 9-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 20:CLASS

Generic attributes :

15:

Saturation : Unsaturated

16:

Saturation : Unsaturated


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10/673,521



G1 [01], [02]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:01:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 570 TO ITERATE

100.0% PROCESSED 570 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 9968 TO 12832

PROJECTED ANSWERS: 8 TO 329


L2 8 SEA SSS SAM L1

=> d scan

L2 8 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(3-thienylmethyl)amino]- (9CI)

MF C15 H12 N6 O S2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/673,521

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):s l1 sss ful  
'S L1 SSS FUL' IS NOT VALID HERE


To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".  
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):7

L2 8 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(2,3-dihydroxypropyl)(1-phenylethyl)amino]- (9CI)  
MF C21 H22 N6 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 8 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(3-pyridinyl)ethyl]amino]- (9CI)  
MF C17 H15 N7 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(phenylmethyl)-3-pyrrolidinylamino]- (9CI)  
MF C21 H21 N7 O S


10/673,521




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 4-((1-methyl-1-phenylethyl)amino)-6-((1-methyl-1-phenylethyl)amino)-, oxime, mono(trifluoroacetate) (9CI)  
MF C19 H19 N7 O S . C2 H F3 O2

CM 1



CM 2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 4-((1H-indazol-5-ylamino)-6-((1-methyl-1-phenylethyl)amino)- (9CI)  
MF C19 H19 N7 O




10/673,521




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 4-[(2-amino-6-benzothiazolyl)amino]-6-[(1-methyl-1-phenylethyl)amino]- (9CI)  
MF C19 H19 N7 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-chloro-6-methylphenyl)methyl]amino]- (9CI)  
MF C18 H15 Cl N6 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/673,521

=> s l1 sss ful  
FULL SEARCH INITIATED 15:02:13 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 10528 TO ITERATE

100.0% PROCESSED 10528 ITERATIONS 67 ANSWERS  
SEARCH TIME: 00.00.01

L3 67 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 161.76 161.97

FILE 'CAPLUS' ENTERED AT 15:02:20 ON 07 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2005 VOL 143 ISS 7  
FILE LAST UPDATED: 5 Aug 2005 (20050805/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3  
L4 3 L3

=> d l4 1-3 bib hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:944102 CAPLUS  
DN 142:211394  
TI 2-Hydroxy-4,6-diamino-[1,3,5]triazines: A Novel Class of VEGF-R2 (KDR) Tyrosine Kinase Inhibitors  
AU Baidur, Nand; Chadha, Naresh; Brandt, Benjamin M.; Asgari, Davoud; Patch, Raymond J.; Schalk-HiHi, Celine; Carver, Theodore E.; Petrounia, Ioanna P.; Baumann, Christian A.; Ott, Heidi; Manthey, Carl; Springer, Barry A.; Player, Mark R.  
CS Drug Discovery, Johnson Johnson Pharmaceutical Research and Development L.L.C., Cranbury, NJ, 08512, USA  
SO Journal of Medicinal Chemistry (2005), 48(6), 1717-1720  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English


10/673,521

IT 677710-40-6P 797039-40-8P 797039-42-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(2-hydroxy-4,6-diamino-[1,3,5]triazines preparation and VEGF-R2 tyrosine kinase inhibition)


RN 677710-40-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 797039-40-8 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[methyl(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 797039-42-0 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(1-methyl-1-phenylethyl)amino]-, oxime, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 677711-38-5

CMF C19 H19 N7 O S


10/673,521



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 677711-42-1P 797039-43-1P 797039-44-2P


797039-45-3P 797039-46-4P 797039-47-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(2-hydroxy-4,6-diamino-[1,3,5]triazines preparation and VEGF-R2 tyrosine kinase inhibition)

RN 677711-42-1 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(1-methylethyl)(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 797039-43-1 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(1-methyl-1-phenylethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 677710-50-8

CMF C19 H18 N6 O S


10/673,521



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 797039-44-2 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 677710-42-8


CMF C17 H14 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 797039-45-3 CAPLUS


10/673,521

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[ethyl(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 677710-39-3


CMF C19 H18 N6 O S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 797039-46-4 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylmethylamino)-6-[(1-methyl-1-phenylethyl)amino]- (9CI). (CA INDEX NAME)



RN 797039-47-5 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(1H-indazol-6-ylamino)-6-[(1-methyl-1-phenylethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 677711-15-8

CMF C19 H19 N7 O


10/673,521



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT **677711-38-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(2-hydroxy-4,6-diamino-[1,3,5]triazines preparation and VEGF-R2 tyrosine kinase inhibition)

RN 677711-38-5 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(1-methyl-1-phenylethyl)amino]-, oxime (9CI) (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:308437 CAPLUS

DN 140:321387

TI Preparation of diaminotriazinols as protein tyrosine kinase inhibitors

IN Player, Mark R.; Baindur, Nand; Brandt, Benjamin; Asgari, Davoud; Chadha, Naresh

PA 3-Dimensional Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

10/673,521

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031184	A1	20040415	WO 2003-US30491	20030929
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1549645	A1	20050706	EP 2003-754941	20030929
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 2004110758	A1	20040610	US 2003-673521	20030930
PRAI	US 2002-414636P	P	20021001		
	WO 2003-US30491	W	20030929		

OS MARPAT 140:321387

IT 677710-39-3P 677710-40-6P 677710-42-8P  
677710-43-9P 677710-44-0P 677710-45-1P  
677710-46-2P 677710-47-3P 677710-48-4P  
677710-50-8P 677710-51-9P 677710-52-0P  
677710-53-1P 677710-54-2P 677710-55-3P  
677710-56-4P 677710-57-5P 677710-59-7P  
677710-60-0P 677710-61-1P 677710-62-2P  
677710-63-3P 677710-66-6P 677710-67-7P  
677710-68-8P 677710-69-9P 677710-70-2P  
677711-13-6P 677711-15-8P 677711-16-9P  
677711-17-0P 677711-18-1P 677711-19-2P  
677711-20-5P 677711-21-6P 677711-22-7P  
677711-24-9P 677711-27-2P, 4-(Benzothiazol-6-ylamino)-6-[benzyl(3-morpholin-4-ylpropyl)amino]-[1,3,5]triazin-2-ol  
677711-28-3P, 4-(Benzothiazol-6-ylamino)-6-[benzyl[3-(4-methylpiperazin-1-yl)propyl]amino]-[1,3,5]triazin-2-ol  
677711-29-4P, 4-(Benzothiazol-6-ylamino)-6-[benzyl(3-dimethylaminopropyl)amino]-[1,3,5]triazin-2-ol 677711-30-7P  
677711-31-8P 677711-32-9P, 4-(Benzothiazol-6-ylamino)-6-[benzyl(2-dimethylaminoethyl)amino]-[1,3,5]triazin-2-ol  
677711-34-1P, 4-(2-Aminobenzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol 677711-35-2P  
677711-36-3P 677711-37-4P 677711-38-5P  
677711-39-6P 677711-40-9P 677711-41-0P,  
4-(Benzothiazol-6-ylamino)-6-[ethyl(pyridin-2-ylmethyl)amino]-[1,3,5]triazin-2-ol 677711-42-1P, 4-(Benzothiazol-6-ylamino)-6-(N-benzylisopropylamino)-[1,3,5]triazin-2-ol 677711-44-3P  
677711-45-4P, 4-(Benzothiazol-6-ylamino)-6-[benzyl(2,2,2-trifluoroethyl)amino]-[1,3,5]triazin-2-ol 677711-46-5P,  
3-[[4-(Benzothiazol-6-ylamino)-6-hydroxy-[1,3,5]triazin-2-yl](1-phenylethyl)amino]propane-1,2-diol 677711-47-6P  
677711-49-8P 677711-50-1P 677711-53-4P,  
4-(Benzothiazol-6-ylamino)-6-(N-benzylpropylamino)-[1,3,5]triazin-2-ol  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of diaminotriazinols as protein tyrosine kinase




10/673,521

inhibitors)


RN 677710-39-3 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-  
[ethyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677710-40-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-  
[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 677710-42-8 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(phenylmethyl)amino]-  
(9CI) (CA INDEX NAME)




RN 677710-43-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[ (1R)-1-  
phenylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/673,521



RN 677710-44-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[ (1S)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677710-45-1 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[methyl[ (1R)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677710-46-2 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[methyl[ (1S)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/673,521



RN 677710-47-3 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[ethyl[(1R)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677710-48-4 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[ethyl[(1S)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677710-50-8 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(1-methyl-1-phenylethyl)amino]- (9CI) (CA INDEX NAME)

10/673,521




RN 677710-51-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 677710-52-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[methyl(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 677710-53-1 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[ethyl(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 677710-54-2 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(2-phenylethyl)ethyl]amino]- (9CI) (CA INDEX NAME)


10/673,521

chlorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 677710-55-3 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(2-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 677710-56-4 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 677710-57-5 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2,6-difluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 677710-59-7 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[methyl[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

10/673,521




RN 677710-60-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677710-61-1 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(phenylmethyl)[1-(phenylmethyl)-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)




RN 677710-62-2 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[3-(3-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 677710-63-3 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-chloro-6-methylphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 677710-66-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677710-67-7 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 677710-68-8 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(1-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 677710-69-9 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

10/673,521




RN 677710-70-2 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[1-(1-naphthalenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 677711-13-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2,4-difluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 677711-15-8 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(1H-indazol-6-ylamino)-6-[(1-methyl-1-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-16-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(2-hydroxy-1-phenylethyl)amino]- (9CI) (CA INDEX NAME)




10/673,521




RN 677711-17-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(1H-indazol-5-ylamino)-6-[(1-methyl-1-phenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-18-1 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(7-benzothiazolylamino)-6-[(1-methyl-1-phenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-19-2 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(2-furanylmethyl)amino]- (9CI) (CA INDEX NAME)

10/673,521




RN 677711-20-5 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(2-thienylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-21-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(3-furanylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-22-7 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(3-thienylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-24-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(phenylmethyl)-3-pyrrolidinylamino]- (9CI) (CA INDEX NAME)




RN 677711-27-2 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[3-(4-morpholinyl)propyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-28-3 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[3-(4-methyl-1-piperazinyl)propyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-29-4 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[3-(dimethylamino)propyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-30-7 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(phenylmethyl)[2-(1-piperazinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

10/673,521




RN 677711-31-8 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(4-morpholinyl)ethyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-32-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(dimethylamino)ethyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-34-1 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-[(2-amino-6-benzothiazolyl)amino]-6-[(1-methyl-1-phenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-35-2 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-[(1-methyl-1-phenylethyl)amino]-6-(6-quinolinylamino)- (9CI) (CA INDEX NAME)

10/673,521




RN 677711-36-3 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-[ethyl(phenylmethyl)amino]-6-(6-quinolinylamino)- (9CI) (CA INDEX NAME)




RN 677711-37-4 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-[methyl(phenylmethyl)amino]-6-(6-quinolinylamino)- (9CI) (CA INDEX NAME)



RN 677711-38-5 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(1-methyl-1-phenylethyl)amino]-, oxime (9CI) (CA INDEX NAME)




RN 677711-39-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[[4-fluoro-3-(1-methyl-1-phenylethyl)amino]-4,5-dihydro-2H-benzothiazol-2-yl]amino]-, oxime (9CI) (CA INDEX NAME)


10/673,521

(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 677711-40-9 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]-6-(6-quinolinylamino)- (9CI) (CA INDEX NAME)




RN 677711-41-0 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[ethyl(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-42-1 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(1-methylethyl)(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-44-3 CAPLUS


CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[ethyl[(2-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

10/673,521




RN 677711-45-4 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(phenylmethyl)(2,2,2-trifluoroethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-46-5 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(2,3-dihydroxypropyl)(1-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-47-6 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(1H-imidazol-4-yl)ethyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-49-8 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[2-(1H-imidazol-4-yl)ethyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 677711-50-1 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[[3-(1H-imidazol-1-yl)propyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 677711-53-4 CAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-(6-benzothiazolylamino)-6-[(phenylmethyl)propylamino]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:513676 CAPLUS

DN 133:120679

TI Preparation of heterocyclyl amino acid derivatives as inhibitors of leukocyte adhesion mediated by VLA-4

IN Konradi, Andrei W.; Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan; Sarantakis, Dimitrios; Welmaker, Gregory S.; Kreft, Anthony; Semko, Christopher; Sullivan, Robert Warren; Soares, Christopher Joseph; Ly, Kiev Sui; Tarby, Christine M.

PA Elan Pharmaceuticals, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 305 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000043369	A1	20000727	WO 2000-US1540	20000121



W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2359113 AA 20000727 CA 2000-2359113 20000121

EP 1144384 A1 20011017 EP 2000-904487 20000121

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

US 6479492 B1 20021112 US 2000-489378 20000121

US 6492372 B1 20021210 US 2000-489377 20000121

ZA 2001005314 A 20030327 ZA 2001-5314 20010627

US 2003125324 A1 20030703 US 2002-218366 20020815

US 6911439 B2 20050628

US 2003144328 A1 20030731 US 2002-218445 20020815

US 6903088 B2 20050607

US 2003139402 A1 20030724 US 2002-251442 20020920

NZ 529822 A 20031219 NZ 2003-529822 20031127

US 2004147512 A1 20040729 US 2003-748089 20031229

PRAI US 1999-116923P A2 19990122

US 1999-160999P P 19991021

US 2000-489377 A3 20000121

US 2000-489378 A3 20000121

WO 2000-US1540 W 20000121

US 2002-251442 A1 20020920

OS MARPAT 133:120679

IT **285563-81-7P**


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclyl amino acid derivs. as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 285563-81-7 CAPLUS

CN L-Tyrosine, N-[6-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)amino]-1,4-dihydro-4-oxo-1,3,5-triazin-2-yl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/673,521

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.62

172.59

STN INTERNATIONAL LOGOFF AT 15:02:48 ON 07 AUG 2005